Lectin from Sambucus sieboldiana abrogates the anoikis resistance of colon cancer cells conferred by N-acetylglucosaminyltransferase V during hematogenous metastasis
Metrics: PDF 1422 views | HTML 2182 views | ?
Kyoung Jin Song1,*, Seong Kook Jeon1,3,*, Su Bin Moon1,6, Jin Suk Park1,6, Jang Seong Kim2,6, Jeongkwon Kim3, Sumin Kim4,5, Hyun Joo An4,5, Jeong-Heon Ko1,6 and Yong-Sam Kim1,6
1Genome Editing Research Center, KRIBB, Daejeon, South Korea
2Biotherapeutics Translational Research Center, KRIBB, Daejeon, South Korea
3Department of Chemistry, Chungnam National University, Daejeon, South Korea
4Graduate School of Analytical Science and Technology, Chungnam National University, Daejeon, South Korea
5Asia-Pacific Glycomics Reference Site, Daejeon, South Korea
6Department of Biomolecular Science, Korea University of Science and Technology, Daejeon, South Korea
*These authors have contributed equally to this work
Yong-Sam Kim, email: firstname.lastname@example.org
Jeong-Heon Ko, email: email@example.com
Keywords: anoikis, metastasis, MGAT5, SSA
Received: September 26, 2016 Accepted: January 08, 2017 Published: February 02, 2017
Anoikis is a form of anchorage-dependent apoptosis, and cancer cells adopt anokis-resistance molecular machinery to conduct metastasis. Here, we report that N-acetylglucosaminyltransferase V gene expression confers anoikis resistance during cancer progression. Overexpression of N-acetylglucosaminyltransferase V protected detached cancer cells from apoptotic death, and suppression or knockout of the gene sensitized cancer cells to the apoptotic death. The gene expression also stimulated anchorage-dependent as well as anchorage-independent colony formation of cancer cells following anoikis stress treatments. Importantly, treatment with the lectin from Sambucus sieboldiana significantly sensitized anoikis-induced cancer cell deaths in vitro as well as in vivo. We propose that the lectin alone or an engineered form could offer a new therapeutic treatment option for cancer patients with advanced tumors.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.